china trial recruitment sept 2011
DESCRIPTION
Current Issues in China Clinical Trial Patient Recruitment and RetentionTRANSCRIPT
![Page 1: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/1.jpg)
Recruitment and
RetentionA Resource Review for Strategic Planning Clinical Trials in CHINA
Ying Lu
Consulting
January, 2012
![Page 2: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/2.jpg)
INTRODUCTION0 One of the biggest hindrances to clinical trials is the lack of patient
participation. Failure of patient recruitment and retention is the
most common cause of delays in market-launch in the US.
Competing for patient resources and failure of investigators to meet
planned patient recruitment goals are also common problems in
clinical trials in China. Despite satisfactory reports of patient
recruitment rates in global trials conducted by major multinational
firms, many local Chinese pharmaceutical trials have difficulty
meeting required timelines due to noncompliance of patients and
investigators, unwillingness of physicians to enroll patients, overly
rigorous inclusion and exclusion criteria, and competing trials.
![Page 3: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/3.jpg)
INTRODUCTION CONT.
0 The majority of the Chinese population seeks out
traditional Chinese Medicine (TCM) and the government
has structured the reforms to favor hospitals with
expertise in TCM. The widespread concurrent use of
TCM with Western pharmaceutical products represents a
challenge with respect to clinical trial design and
interpretation of trial data.
![Page 4: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/4.jpg)
INTRODUCTION CONT.
0 This presentation is to provide resources for planning
and managing clinical trials in China by highlighting
patient populations with major diseases, State Food and
Drug Administration (SFDA) GCP certified clinical trial
sites, and the commonly used Traditional Chinese
Medicine (CTM).
![Page 5: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/5.jpg)
Overview of Chinese Population Growth Rate in Urban and Rural Areas, and by Age Groups
1982 1990 1995 2000 2005 2006 2007 2008 20090
40000
80000
120000
160000
0
20
40
60
80
Urban Rural 0-14 age 15-64 age >65 age
Popu
latio
n (1
0,00
0)
Year
Rat
e (%
)
![Page 6: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/6.jpg)
Ten Leading Course of Death in Urban and Rural Areas
Malignant NeoplasmasCerebrovascular Disease
Heart DiseasesRespiratory System
Injury & PoisoningEndocrine/Nutritional/Metabolic Disorders
Digestive SystemGenitourinary System
Nervous SystemInfectious Diseases
0 50 100 150 200
Rural Urban
Mortality Rate = total deaths ( caused by diseases) at reference period/average population at same period x 100%.
![Page 7: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/7.jpg)
Morbidity Rates of 10 Major Chronic Diseases (%) in Urban & Rural Areas in 2009
Hypertension
DiabetesCerebrovascular diseaseIschaemic heart disease
Intervertebral disc disorderGastroenteritis
Rheumatoid arthritisCOPD
Cholelith & Cholecystitis
Peptic ulcer
0 40 80 120
Rural Urban
Mortality Rate = total deaths ( caused by diseases) at reference period/average population at same period x 100%.
![Page 8: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/8.jpg)
Rates of Urban And Rural Area Outpatient/Office Visits in 2008 (0/00)
Acute Upper Respiratory InfectionHypertension
Heart DiseaseDiabetes
Acute GastritisGenitourinary Diseases
Cerebrovascular DiseasesCOPD
ArthritisCancer
Gallbladder DiseaseInfectious Diseases
PneumoniaCirrhosis
0 10 20 30 40 50
Rural Urban
![Page 9: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/9.jpg)
Rates of Urban and Rural Area Inpatient Hospital Stays in 2008 (0/00)
Heart DiseaseCerebrovascular Diseases
HypertensionCancer
DiabetesGenitourinary Diseases
Gallbladder DiseaseCOPD
Acute Upper Respiratory InfectionPneumonia
Acute GastritisInfectious Diseases
ArthritisCirrhosis
0 2 4 6 8 10
Rural Urban
![Page 10: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/10.jpg)
Two-week Hospital Outpatient Visit Rate by Age in 2008
A
0-4 5-14 15-24 25-34 35-44 45-54 55-64 >650
50
100
150
200
250
300
350Urban Rural
Age (year)
Two-
wee
k ho
spita
l vis
it ra
te b
y ag
e (‰
)
![Page 11: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/11.jpg)
Two-week Hospital Outpatient Visit Rate by Hospital Level & Preference (2008)
![Page 12: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/12.jpg)
Percentage of Drug and Traditional Chinese Medicine Usages
![Page 13: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/13.jpg)
Urban and Rural Household Income and Healthcare Expenditure (Yuan, 2008)
Urban Rural0
4000
8000
12000
16000 Disposable Income, 15,781
Net Income, 4,761
Non-productive Expenditure;
11,243
Non-productive Expenditure;
3,661Healthcare; 786 Healthcare; 246
Yuan
![Page 14: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/14.jpg)
Average Expenses of General Hospital Outpatient Visits and Inpatient Stays (Yuan/per patient, 2008)
Medication Diagnostic & Treatment
Other10
100
1000
10000
Out-patient (per visit) In-patient (per patient)
Patie
nt F
ee (Y
uan)
![Page 15: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/15.jpg)
Current China Clinical Trials Registered in Chinese Clinical Trial Registry
![Page 16: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/16.jpg)
Overview of 10 Year New Chemical Entity (NEC) SFDA Applications
2001-2010 Class I New Chemical Entity SFDA Application
![Page 17: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/17.jpg)
SUMMARY0 Mortality rates of major diseases were relatively higher in
rural than in urban areas. Morbidity rates of cardiovascular disease and diabetes were higher in cities, and morbidity rates of acute upper respiratory infection, pneumonia, acute gastritis, infection, cirrhosis were higher in countries. High two-week hospital visit rate was reported in rural area by all age groups. People in rural area were less likely visit above prefecture-level hospitals. Short distance and high level expertise of physicians were major factors for selecting hospital visits. Current SFDA GCP certified over 400 clinical trial sites are hospitals at above county levels, therefore including patients in rural areas can be a challenge.
![Page 18: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/18.jpg)
SUMMARY CONT.
0 Although incidences of infectious diseases were relative low, anti-microbial agents were top rated drugs used in hospitals. Main applications of Traditional Chinese medicine (TCM) were Cardio/Cerebrovascular diseases, cancer, respiratory diseases, and musculoskeletal disorders. Wide use of TCM and other medications might require extra caution on designing and selecting study subjects. Majority China clinical trials can be found at clicinaltiral.gov (NIH) and Chinese Clinical Trial Registry; these are good resources for identify competing trials for study subjects. Information presented above might provide valuable resources for analyzing threats and opportunities in China clinical trial patient recruitment and retention.
![Page 19: China Trial Recruitment Sept 2011](https://reader035.vdocument.in/reader035/viewer/2022062514/5590e8ed1a28ab06148b469e/html5/thumbnails/19.jpg)
REFERENCES AND USEFUL LINKS
• Health statistics: http://www.stats.gov.cn/tjsj/ndsj/2010/indexeh.htm• pre-clinical study site list:
http://app1.sfda.gov.cn/datasearch/face3/base.jsp?tableId=11&tableName=TABLE11&title=临床前研究单位备案名单&bcId=118714711342967566418335831165
• SFDA GCP certified study site list: http://app1.sfda.gov.cn/datasearch/face3/base.jsp?tableId=19&tableName=TABLE19&title=药物临床试验机构名单&bcId=118714941832181502104731901420
• SFDA new drug clinical trial list: http://app1.sfda.gov.cn/datasearch/face3/base.jsp?tableId=8&tableName=TABLE8&title=%C5%FA%D7%BC%C1%D9%B4%B2%D1%D0%BE%BF%B5%C4%D0%C2%D2%A9&bcId=124356683643430217478147499292